Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Proper Name Review Memorandum, September 2, 2009 - MenHibrix

DATE:September 2, 2009
FROM:Joseph J. Temenak, Ph.D.Chair, Biologics License Application STN 125363
SUBJECT: Proper name review for GlaxoSmithKline Biologicals’ Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine (proposed proprietary name: MenHibrix)   


The proper name proposed by GSK, “Meningococcal Groups C and Y and
Haemophilus b Tetanus Toxoid Conjugate Vaccine”, is consistent with other licensed vaccines that contain similar components and with the OVRR memorandum, “Guideline for Non-proprietary Vaccine Names” dated December 19, 2007.  The OVRR memorandum was provided by Dr. Marion Gruber (IOD-OVRR) to assist in the review of the proposed proper name.

In my view, the proper name proposed by GSK is acceptable.

Page Last Updated: 07/15/2012
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English